Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...
The biggest stories of the day delivered to your inbox.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback